As the worldwide population ages, the incidence of end-stage renal disease (ESRD) will continue to escalate, facilitating the need for increased dialysis services and products, a global market worth nearly $54.0 billion in 2006. According to The Worldwide Market for Dialysis Equipment, Supplies and Services, a new study from medical market research firm Kalorama Information, the incidence of ESRD should increase from 1.9 million cases to 2.7 million cases by 2011, driving the dialysis market to well beyond $73.0 billion that year.
While the market currently services only 79% or 1.5 million of those suffering from renal issues, market growth from 2005 to 2011 is expected to be a healthy 6.2% as not only the incidence of renal disease escalates but the availability of treatments becomes more widespread. Experts predict that industry growth will mainly be led by volume increases in Asia, Latin America and Africa where the market is largely untapped and the infrastructure for dialysis treatments is continually improving.
Composed of two segments, the global dialysis market is dominated by dialysis services which provide 82% of the industry revenues. The dialysis products and supplies segment, including hemodialysis and peritoneal products and currently valued at $9.8 billion, makes up the remaining 18% of the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze